The Use of Prognostic Factors in Inflammatory Bowel Diseases

被引:23
作者
Billiet T. [1 ]
Ferrante M. [1 ]
Van Assche G. [1 ]
机构
[1] Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, Leuven
关键词
Crohn’s disease; Genetics; IBD; Personalized medicine; Prognostic factors; Serological markers; Ulcerative colitis;
D O I
10.1007/s11894-014-0416-y
中图分类号
学科分类号
摘要
The disease spectrum and natural course of Crohn’s disease and ulcerative colitis are highly variable. The majority of Crohn’s disease patients will require surgery at a certain stage in their disease compared to only a fraction of the ulcerative colitis patients. Similarly, some patients are destined to experience an indolent disease course while others will require early intensive therapy. Ideally, these subtypes of patients should be identified as early as possible with the help of reliable prognostic factors in order to guide personalized therapeutic decisions. In this review, the authors focused on the most relevant reports on the use of different prognostic factors to predict disease course, postoperative recurrence and response to therapy in patients with inflammatory bowel disease. The last 15 years have seen a wealth of novel genetic and serological markers of disease severity. Nevertheless, none of these markers have proven to be superior to careful clinical phenotyping and endoscopic features early in the disease course. Future attempts should apply an integrated approach that unites clinical, serological and (epi)genetic information with environmental influences, with a clear focus on the microbiome to ultimately identify molecular-based and clinically relevant subgroups. © 2014, Springer Science+Business Media New York.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 139 条
[1]  
Abraham C., Cho J.H., Inflammatory bowel disease, N Engl J Med, 361, 21, pp. 2066-2078, (2009)
[2]  
Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., Et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease, Nature, 491, 7422, pp. 119-124, (2012)
[3]  
Cosnes J., Gower-Rousseau C., Seksik P., Cortot A., Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology, 140, 6, pp. 1785-1794, (2011)
[4]  
Jess T., Riis L., Vind I., Winther K.V., Borg S., Binder V., Et al., Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark, Inflamm Bowel Dis, 13, 4, pp. 481-489, (2007)
[5]  
D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., Et al., Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial, Lancet, 371, 9613, pp. 660-667, (2008)
[6]  
Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Et al., Infliximab, azathioprine, or combination therapy for Crohn’s disease, N Engl J Med, 362, 15, pp. 1383-1395, (2010)
[7]  
Billiet T., Rutgeerts P., Ferrante M., Van Assche G., Vermeire S., Targeting TNF-alpha for the treatment of inflammatory bowel disease, Expert Opin Biol Ther, 14, 1, pp. 75-101, (2014)
[8]  
Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., Et al., Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, pp. 5a-36a, (2005)
[9]  
Krishnaprasad K., Andrews J.M., Lawrance I.C., Florin T., Gearry R.B., Leong R.W., Et al., Inter-observer agreement for Crohn’s disease sub-phenotypes using the Montreal Classification: how good are we? A multi-centre Australasian study, J Crohns Colitis, 6, 3, pp. 287-293, (2012)
[10]  
Main J., McKenzie H., Yeaman G.R., Kerr M.A., Robson D., Pennington C.R., Et al., Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease, BMJ, 297, 6656, pp. 1105-1106, (1988)